Skip to Content
  • Previous Rank
    316
  • Revenues ($M)
    $30,390
  • Revenue Percent Change
    -6.9%
  • Profits ($M)
    $13,501
  • Profits Percent Change
    -25.4%
  • Assets ($M)
    $56,977
  • Employees
    9,000

Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

CEO
John F. Milligan
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Foster City, CA
Websitehttp://www.gilead.com
Years on Global 500 List3
Employees9,000

Gilead Sciences Rank History

placeholder

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$30,390-6.9%
Profits ($M)$13,501-25.4%
Assets ($M)$56,977-
Total Stockholder Equity ($M)$18,887-

Profit Ratios

Profit as % of Revenues44.4%
Profits as % of Assets23.7%
Profits as % of Stockholder Equity71.5%